International
The Morning Science

What science found today

‹
 

Research

Malaria vaccine shows 87% efficacy in clinical trial

Medical Xpress ·

Malaria vaccine shows 87% efficacy in clinical trial

The Brief

  • A genetically attenuated whole-parasite malaria vaccine, PfSPZ-LARC2, showed 87% efficacy in preventing infection in a recent phase 1 trial.
  • The figure is reported by Medical Xpress in a story dated 2026-11-20.
  • The source does not give trial size, population, or follow-up details.

Why it matters

A reported 87% efficacy against infection in a phase 1 trial is an early signal for a whole-parasite malaria vaccine approach, but phase 1 results alone do not establish protection in wider populations.

Who’s affected

  • malaria researchers and vaccinologists
  • global health practitioners following malaria vaccine development

The novel, genetically attenuated whole-parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.

How do you feel about this?

0 Comments

    Malaria vaccine shows 87% efficacy in clinical trial – The Morning Science